水晶光電(002273.SZ)子公司將獲政府補助4750萬元 已到賬1600萬元
格隆匯9月25日丨水晶光電(002273.SZ)宣佈,公司下屬全資子公司江西水晶光電有限公司(下稱“江西水晶”)於近日接到鷹潭高新技術產業開發區管理委員會下發的《關於下達2020年鷹潭高新區物聯網企業高質量發展獎勵資金的通知》(鷹高新字[2020]83號)。
為表彰江西水晶長期以來對鷹潭高新區物聯網及智能終端產業的培育發展所作出的卓越貢獻,經鷹潭高新區管委會研究決定,對江西水晶下達物聯網企業高質量發展獎勵資金4750萬元人民幣。截至該公告日,首次撥付的政府獎勵資金1600萬元人民幣已到賬。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.